Machine learning and artificial intelligence may be the future of medicine.
Many psychiatric disorders have complex biomarkers that direct treatment. Some of these are comorbid, like anxiety plus depression or ADHD plus anxiety. It can be challenging to differentiate between the disorders due to overlapping systems.
Machine learning technology may help in more precise diagnosis of disorders. It looks for very specific patterns to help narrow diagnosis.
Listen as Dr. Kristen Willeumier joins Dr. Mike Smith to discuss innovations in machine learning to improve psychiatric treatment.
Learn more about Dr. Willeumier at www.drwilleumier.com.
Machine Learning & Psychiatry
Featuring:
in clinical practice. She has authored or co-authored over 50 scientific publications in peer reviewed journals. Areas of published research include traumatic brain injury, posttraumatic stress disorder, autism, biomarkers of suicide, obesity, gender differences in brain function, clinical outcomes and brain rehabilitation. Together with colleagues, she led a clinical research trial investigating the long-term effects of repetitive subconcussive impacts in NFL football players. Subsequent work focused on
therapeutic approaches to rehabilitate brain function in athletes and the application of machine learning algorithms to neuroimaging data to improve the diagnosis and treatment of psychiatric disorders.
Dr. Willeumier conducted her graduate research in the laboratory of Neurophysiology at the University of California, Los Angeles and the laboratory of Neurogenetics at Cedars-Sinai Medical Center using live cell imaging to investigate mechanisms of synaptic signaling in Parkinson’s disease. She received MS degrees in Physiological science and Neurobiology and a PhD degree in Neurobiology from the University of California, Los Angeles. She was a post-doctoral fellow in the Department of Neurology at
Cedars-Sinai Medical Center where she continued her work in the field of neurodegenerative disease.
She was also a Senior Research Fellow with the Society for Brain Mapping and Therapeutics. She was the recipient of an NIH fellowship award from the National Institute of Mental Health to study the molecular mechanisms underlying Parkinson’s disease and has presented her work at national and international scientific meetings including the Society for Neuroscience and Gordon Research Conference in Hong Kong.
Kristen Willeumier, PhD
Kristen Willeumier, PhD, is a neuroscientist with research expertise on how diet, lifestyle, nutrition and sports related concussions impact brain health and longevity. Dr. Willeumier served as the Director of Neuroimaging Research for the Amen Clinics from 2009-2016 exploring the role of brain SPECT imagingin clinical practice. She has authored or co-authored over 50 scientific publications in peer reviewed journals. Areas of published research include traumatic brain injury, posttraumatic stress disorder, autism, biomarkers of suicide, obesity, gender differences in brain function, clinical outcomes and brain rehabilitation. Together with colleagues, she led a clinical research trial investigating the long-term effects of repetitive subconcussive impacts in NFL football players. Subsequent work focused on
therapeutic approaches to rehabilitate brain function in athletes and the application of machine learning algorithms to neuroimaging data to improve the diagnosis and treatment of psychiatric disorders.
Dr. Willeumier conducted her graduate research in the laboratory of Neurophysiology at the University of California, Los Angeles and the laboratory of Neurogenetics at Cedars-Sinai Medical Center using live cell imaging to investigate mechanisms of synaptic signaling in Parkinson’s disease. She received MS degrees in Physiological science and Neurobiology and a PhD degree in Neurobiology from the University of California, Los Angeles. She was a post-doctoral fellow in the Department of Neurology at
Cedars-Sinai Medical Center where she continued her work in the field of neurodegenerative disease.
She was also a Senior Research Fellow with the Society for Brain Mapping and Therapeutics. She was the recipient of an NIH fellowship award from the National Institute of Mental Health to study the molecular mechanisms underlying Parkinson’s disease and has presented her work at national and international scientific meetings including the Society for Neuroscience and Gordon Research Conference in Hong Kong.
Dr. Willeumier is currently the on the Scientific Advisory Board of Tate Technology, LLC, a sports safety and technology licensing company.